scholarly journals 3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence

2018 ◽  
Vol 49 (3) ◽  
pp. 719-730 ◽  
Author(s):  
Jin Wang ◽  
Qungang Shan ◽  
Yong Liu ◽  
Hao Yang ◽  
Sichi Kuang ◽  
...  
Keyword(s):  
Tumor Recurrence ◽  
Mr Elastography ◽  
Hepatocellular Carcinomas ◽  
Potential Biomarker

scholarly journals Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas

Oncotarget ◽  
2018 ◽  
Vol 9 (25) ◽  
pp. 17895-17905 ◽  
Author(s):  
Francesco Vasuri ◽  
Silvia Fittipaldi ◽  
Vanessa De Pace ◽  
Laura Gramantieri ◽  
Valentina Bertuzzo ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Tumor Recurrence ◽  
Hepatocellular Carcinomas

Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas

2003 ◽  
Vol 35 (5) ◽  
pp. 1830-1831 ◽  
Author(s):  
N.J De la Revilla ◽  
J.M Moreno ◽  
E Rubio ◽  
T.A de Herreros ◽  
E Navarrete ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Tumor Recurrence ◽  
Hepatocellular Carcinomas

scholarly journals Loss of expression of Syndecan-1 is associated with Tumor Recurrence, Metastatic Potential, and Poor Survival in patients with Colorectal carcinoma

2020 ◽  
Vol 37 (1) ◽  
Author(s):  
Jaudah Ahmed Al-Maghrabi
Keyword(s):  
Colorectal Carcinoma ◽  
Poor Prognosis ◽  
Tumor Recurrence ◽  
Disease Free Survival ◽  
Metastatic Potential ◽  
University Hospital ◽  
Clinicopathological Parameters ◽  
Poor Survival ◽  
Primary Tumors ◽  
Potential Biomarker

Objective: The loss of expression of syndecansyndecan-1 is associated with poor prognosis in many types of human cancer. The objective of this study was to evaluate the relation between syndecan-1 immunoexpression and several clinicopathological parameters in a subset of colorectal carcinoma (CRC) patients. Methods: Pathology tissue blocks of 202 primary tumors, 41 adenomas, and 37 normal colonic mucosae were used in this study. The cases diagnosed in the period 1995–2015 was included in the study. Immunohistochemistry analysis was performed using anti-CD138/syndecan-1 (B-A38) mouse monoclonal antibody. A semiquantitative method was used to score the syndecan-1 expression based on an evaluation of the percentage and intensity of the membranous and cytoplasmic expression. The data collected from Pathology Department at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. This is a retrospective cohort study that was conducted from July 2018 until August 2019. Results: Loss of syndecan-1 immunoexpression was observed in 72 (42.6%), 5 (12.2%), and 3 (8.1%) cases of CRC, adenomas, and normal mucosae, respectively. Low expression of syndecan-1 showed an association with nodal (p=0.003) and distant (p=0.001) metastasis, lymphovascular invasion (p=0.001), and tumor recurrence (p=0.006). Low syndecan-1 expression were associated with short overall survival (OS) (log rank 4.019, p=0.045) and disease-free survival (DFS) probabilities (log rank 4.748, p=0.029). Conclusion: Loss of syndecan-1 immunoexpression is associated with metastatic potential, tumor recurrence and shorter survival in CRC and is considered a potential biomarker of poor prognosis in CRC patients. doi: https://doi.org/10.12669/pjms.37.1.2592 How to cite this:Al-Maghrabi J. Loss of expression of Syndecan-1 is associated with Tumor Recurrence, Metastatic Potential, and Poor Survival in patients with Colorectal carcinoma. Pak J Med Sci. 2021;37(1):114-120. doi: https://doi.org/10.12669/pjms.37.1.2592 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Tumor Solid Stress: Assessment with MR Elastography under Compression of Patient-Derived Hepatocellular Carcinomas and Cholangiocarcinomas Xenografted in Mice

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1891
Author(s):  
Gwenaël Pagé ◽  
Marion Tardieu ◽  
Jean-Luc Gennisson ◽  
Laurent Besret ◽  
Philippe Garteiser ◽  
...  
Keyword(s):  
Interstitial Fluid ◽  
Liver Tumors ◽  
Fluid Pressure ◽  
Interstitial Fluid Pressure ◽  
Collagen Content ◽  
Mr Elastography ◽  
Solid Stress ◽  
Hepatocellular Carcinomas ◽  
Malignant Liver Tumors ◽  
Malignant Liver

Malignant tumors have abnormal biomechanical characteristics, including high viscoelasticity, solid stress, and interstitial fluid pressure. Magnetic resonance (MR) elastography is increasingly used to non-invasively assess tissue viscoelasticity. However, solid stress and interstitial fluid pressure measurements are performed with invasive methods. We studied the feasibility and potential role of MR elastography at basal state and under controlled compression in assessing altered biomechanical features of malignant liver tumors. MR elastography was performed in mice with patient-derived, subcutaneously xenografted hepatocellular carcinomas or cholangiocarcinomas to measure the basal viscoelasticity and the compression stiffening rate, which corresponds to the slope of elasticity versus applied compression. MR elastography measurements were correlated with invasive pressure measurements and digital histological readings. Significant differences in MR elastography parameters, pressure, and histological measurements were observed between tumor models. In multivariate analysis, collagen content and interstitial fluid pressure were determinants of basal viscoelasticity, whereas solid stress, in addition to collagen content, cellularity, and tumor type, was an independent determinant of compression stiffening rate. Compression stiffening rate had high AUC (0.87 ± 0.08) for determining elevated solid stress, whereas basal elasticity had high AUC for tumor collagen content (AUC: 0.86 ± 0.08). Our results suggest that MR elastography compression stiffening rate, in contrast to basal viscoelasticity, is a potential marker of solid stress in malignant liver tumors.

Hepatitis C Virus Infection is a Risk Factor for Tumor Recurrence after Resection of Small Hepatocellular Carcinomas

2004 ◽  
Vol 28 (8) ◽  
pp. 787-791 ◽  
Author(s):  
Teh-Ia Huo ◽  
Jaw-Ching Wu ◽  
Cheng-Yuan Hsia ◽  
Gar-Yang Chau ◽  
Wing-Yiu Lui ◽  
...  
Keyword(s):  
Risk Factor ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Tumor Recurrence ◽  
Hepatitis C Virus Infection ◽  
Hepatocellular Carcinomas
Sign in / Sign up

Export Citation Format

Share Document